187 related articles for article (PubMed ID: 35168061)
1. Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Park UB; Jeong TJ; Gu N; Lee HT; Heo YS
Biochem Biophys Res Commun; 2022 Apr; 599():31-37. PubMed ID: 35168061
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Lee SH; Lee HT; Lim H; Kim Y; Park UB; Heo YS
Biochem Biophys Res Commun; 2020 Jun; 527(1):226-231. PubMed ID: 32446372
[TBL] [Abstract][Full Text] [Related]
3. The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy.
Jeong TJ; Lee HT; Gu N; Jang YJ; Choi SB; Park UB; Lee SH; Heo YS
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551910
[TBL] [Abstract][Full Text] [Related]
4. Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor.
Liu J; Wang G; Liu L; Wu R; Wu Y; Fang C; Zhou X; Jiao J; Gu Y; Zhou H; Xie Z; Sun Z; Chen D; Dai K; Wang D; Tang W; Yang TTC
Sci Rep; 2019 Nov; 9(1):17830. PubMed ID: 31780710
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Analysis of Dostarlimab Immunogenicity.
Lu S; Bowsher RR; Clancy A; Rosen A; Zhang M; Yang Y; Koeck K; Gao M; Potocka E; Guo W; Jen KY; Im E; Milton A
AAPS J; 2021 Jul; 23(5):96. PubMed ID: 34324079
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Lee JY; Lee HT; Shin W; Chae J; Choi J; Kim SH; Lim H; Won Heo T; Park KY; Lee YJ; Ryu SE; Son JY; Lee JU; Heo YS
Nat Commun; 2016 Oct; 7():13354. PubMed ID: 27796306
[TBL] [Abstract][Full Text] [Related]
8. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
[TBL] [Abstract][Full Text] [Related]
10. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
Commun Biol; 2019; 2():392. PubMed ID: 31667366
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1.
Wang S; Khan FI
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445859
[TBL] [Abstract][Full Text] [Related]
12. The binding epitope of sintilimab on PD-1 revealed by AbMap.
Ma M; Qi H; Hu C; Xu Z; Wu F; Wang N; Lai D; Li Y; Zhang H; Jiang H; Meng Q; Guo S; Kang Y; Zhao X; Li H; Tao SC
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):628-635. PubMed ID: 33637989
[TBL] [Abstract][Full Text] [Related]
13. Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment.
Singh V; Sheikh A; Abourehab MAS; Kesharwani P
Biosensors (Basel); 2022 Aug; 12(8):. PubMed ID: 36005013
[TBL] [Abstract][Full Text] [Related]
14. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
15. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.
Babar Q; Saeed A; Murugappan S; Dhumal D; Tabish T; Thorat ND
Drug Discov Today; 2023 Jun; 28(6):103577. PubMed ID: 37004983
[TBL] [Abstract][Full Text] [Related]
16. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
Tang S; Kim PS
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
[TBL] [Abstract][Full Text] [Related]
17. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
18. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
Liu H; Guo L; Zhang J; Zhou Y; Zhou J; Yao J; Wu H; Yao S; Chen B; Chai Y; Qi J; Gao GF; Tan S; Feng H; Yan J
MAbs; 2019; 11(4):681-690. PubMed ID: 30892132
[TBL] [Abstract][Full Text] [Related]
19. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
Hong Y; Feng Y; Sun H; Zhang B; Wu H; Zhu Q; Li Y; Zhang T; Zhang Y; Cui X; Li Z; Song X; Li K; Liu M; Liu Y
FEBS Open Bio; 2021 Mar; 11(3):782-792. PubMed ID: 33527708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]